TP53 and neoplasm: Likewise, although no somatic mutations were detected by either panel in these 51 samples, as shown in Supplementary Table S2, we confirmed that across evaluable MiMouse-sequenced colorectal carcinoma mouse tumor samples (see below) with introduced human mutations (BRAF p.V600E and TP53 p.R270H), these human mutations were only detected in the nine of nine samples with introduced BRAF p.V600E mutations and the 21 of 22 of samples with TP53 p.R270H mutation, respectively (the sample without the expected mutation minimally passed our usual uniformity QC metric).